NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Filana Therapeutics, Inc. FLNA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-1.88
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-82.7%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
USD -1.88
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-82.7%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-65.9%
Each USD of equity lost 83 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+34.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+37.1%
Change, 10 years—
The share count grew 37% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 118.4M
total assets, end of FY2025
Total assetsUSD 118.4M
EquityUSD 74.4M
CashUSD 95.5M
Current ratio2.23×
Equity funds 63% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
·
·
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
·
·
·
·
·
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
·
·
·
·
·
·
·
·
·
·
−0.0
0.0
0.0
·
−0.0
Net income $B
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.88
−1.46
−2.32
−1.90
−0.82
−0.24
−0.27
−0.61
−1.82
−2.28
−0.31
−0.27
0.70
−0.08
−0.06
−0.28
−0.08
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−82.7
−17.2
−53.3
−31.7
−18.7
−11.1
−22.2
−44.7
−84.1
−61.9
−40.8
−28.0
102.7
−12.0
−6.8
−17.0
−3.2
Shares out B
0.05
0.05
0.04
0.04
0.04
0.04
0.02
0.02
0.01
0.01
0.05
0.05
0.05
0.05
0.04
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed